CD274 and neoplasm: The proportion of patients with PD-L1–positive tumors was similar in the discordant and concordant disease progression subgroups (30.6% and 26.2%, respectively), indicating that discordance between BOR and irBOR assessments by RECIST 1.1 and irRECIST, respectively, was irrespective of tumor PD-L1 status.